More clinical data required for iclaprim application:
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Arpida did not demonstrate efficacy of its anti-infective iclaprim for treatment of complicated skin and skin structure infections within an acceptable non-inferiority margin, FDA says in a "complete response" letter. An additional study showing non-inferiority of intravenous iclaprim to an approved comparator may be sufficient to meet this requirement, depending on study results, Arpida said Jan. 19. A resubmission will likely also provide updated safety data and labeling information. The letter was not a surprise, said CEO Jurgen Raths in a company release; a November advisory panel voted 17-2 against the drug's safety and efficacy (1"The Pink Sheet" DAILY, Nov. 20, 2008). Arpida slashed three-fourths of its workforce and will seek expert advice on further clinical development for iclaprim (2"The Pink Sheet," Dec. 22, 2008, In Brief)
You may also be interested in...
FDA Panel Says Arpida’s Iclaprim Inferior To Comparator
Advisory committee votes down the antibiotic based on the non-inferiority margin and problems with the clinical study and its results.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.